Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Phase IB Part of a Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Monotherapy and In Combination with Immune-Oncology Treatment in Advanced Solid Tumors
Changing the Default for Tobacco Treatment
Study Type: Prevention
Phase: IV
NCTID: NCT02721082
Principal Investigator:
Kimber Richter
A Phase III Study of CG0070 in Patients with Non-Muscle Invasive Bladder Cancer NMIBC Unresponsive to Bacillus-Calmette- Guerin BCG
An Open-Label Expanded Access Program Of Futibatinib TAS-120 In Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements
Study Type: Treatment
Phase: II
NCTID: NCT04507503
Principal Investigator:
Ravi Chuda
A Phase 2 Study of Dabrafenib NSC 763760 with Trametinib NSC 763093 after Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma HGG
Study Type: Treatment
Phase: II
NCTID: NCT03919071
Principal Investigator:
Keith August
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin NSC: 772518 for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Study Type: Treatment
Phase: III
NCTID: NCT03959085
Principal Investigator:
Keith August
A Phase I/II Study of Nivolumab plus or minus Ipilimumab in Combination with Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma
Phase I/IB Open-Label, Dose-Escalation Study of APVO436 in Patients With Relapsed or Refractory AML or High-Grade MDS
A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Brutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients 65 years of age with Chronic Lymphocytic Leukemia CLL
Phase IIIb, Open-label study evaluating the efficacy and safety of luspatercept BMS-986346/ACE-536 initiated at maximum approved dose in LR-MDS with IPSS-R very low, low or intermediate risk who require RBC transfusions MAXILUS
Study Type: Treatment
Phase: III
NCTID: NCT06045689
Principal Investigator:
Jesus Gonzalez Lugo